One shot gene therapy aims to halt vision loss in rare eye disorders
NCT ID NCT06460844
First seen Feb 26, 2026 · Last updated May 22, 2026 · Updated 12 times
Summary
This early-stage study tests a single injection of RTx-015 into the eye for people with retinitis pigmentosa or choroideremia, two inherited conditions that cause progressive vision loss. About 18 adults will receive one of four doses and be monitored for 5 years to check safety and any changes in eyesight. The goal is to see if the treatment is safe enough to move to larger trials.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RETINITIS PIGMENTOSA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Retina Consultants of Texas Research Centers
Bellaire, Texas, 77401, United States
-
Retina Vitreous Associates Medical Group
Beverly Hills, California, 90211, United States
-
UCI Alpha Clinic
Orange, California, 92868, United States
-
UPMC Vision Institute
Pittsburgh, Pennsylvania, 15221, United States
Conditions
Explore the condition pages connected to this study.